These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20335225)

  • 1. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures.
    Pan H; Myerson JW; Ivashyna O; Soman NR; Marsh JN; Hood JL; Lanza GM; Schlesinger PH; Wickline SA
    FASEB J; 2010 Aug; 24(8):2928-37. PubMed ID: 20335225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.
    Zhang Z; Chen J; Ding L; Jin H; Lovell JF; Corbin IR; Cao W; Lo PC; Yang M; Tsao MS; Luo Q; Zheng G
    Small; 2010 Feb; 6(3):430-7. PubMed ID: 19957284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles.
    Wang J; Dzuricky M; Chilkoti A
    Nano Lett; 2017 Oct; 17(10):5995-6005. PubMed ID: 28853896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-Assisted Nucleic Acid Delivery Systems on the Rise.
    Tarvirdipour S; Skowicki M; Schoenenberger CA; Palivan CG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia.
    Bose RJ; Kim BJ; Arai Y; Han IB; Moon JJ; Paulmurugan R; Park H; Lee SH
    Biomaterials; 2018 Dec; 185():360-370. PubMed ID: 30273835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multistage Continuous Targeting with Quantitatively Controlled Peptides on Chitosan-Lipid Nanoparticles with Multicore-Shell Nanoarchitecture for Enhanced Orally Administrated Anticancer In Vitro and In Vivo.
    Su CW; Yen CS; Chiang CS; Hsu CH; Chen SY
    Macromol Biosci; 2017 Feb; 17(2):. PubMed ID: 27634372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmable nanoparticle functionalization for in vivo targeting.
    Pan H; Myerson JW; Hu L; Marsh JN; Hou K; Scott MJ; Allen JS; Hu G; San Roman S; Lanza GM; Schreiber RD; Schlesinger PH; Wickline SA
    FASEB J; 2013 Jan; 27(1):255-64. PubMed ID: 23047896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
    Saad M; Garbuzenko OB; Ber E; Chandna P; Khandare JJ; Pozharov VP; Minko T
    J Control Release; 2008 Sep; 130(2):107-14. PubMed ID: 18582982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessments of crucial factors for a functional ligand-targeted nanocarrier.
    Hossen MN; Kajimoto K; Tatsumi R; Hyodo M; Harashima H
    J Drug Target; 2014 Aug; 22(7):600-9. PubMed ID: 24806515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
    Koning GA; Krijger GC
    Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid based nanocarriers: a translational perspective.
    Mishra DK; Shandilya R; Mishra PK
    Nanomedicine; 2018 Oct; 14(7):2023-2050. PubMed ID: 29944981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances.
    Shreya AB; Raut SY; Managuli RS; Udupa N; Mutalik S
    AAPS PharmSciTech; 2018 Dec; 20(1):15. PubMed ID: 30564942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
    Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
    Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active targeting of brain tumors using nanocarriers.
    Béduneau A; Saulnier P; Benoit JP
    Biomaterials; 2007 Nov; 28(33):4947-67. PubMed ID: 17716726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.
    Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V
    Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.
    Juliano RL; Alam R; Dixit V; Kang HM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(3):324-35. PubMed ID: 20049800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.
    Martins S; Sarmento B; Ferreira DC; Souto EB
    Int J Nanomedicine; 2007; 2(4):595-607. PubMed ID: 18203427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.
    Din FU; Aman W; Ullah I; Qureshi OS; Mustapha O; Shafique S; Zeb A
    Int J Nanomedicine; 2017; 12():7291-7309. PubMed ID: 29042776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications.
    Sala M; Diab R; Elaissari A; Fessi H
    Int J Pharm; 2018 Jan; 535(1-2):1-17. PubMed ID: 29111097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.